A Phase 3 interventional study of Human Insulin Inhalation Powder and injected insulin in Diabetes Mellitus, Asthma and Pulmonary Disease, Chronic Obstructive, sponsored by Eli Lilly and Company. Completed at 101 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-17.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing Insulin, Regular, Human in Diabetes Mellitus — 2 open to participants now, 2 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus.
Among the 41 studies testing Insulin, Regular, Human in Diabetes Mellitus, this one is the 8th largest by enrollment, is one of 3 that started in 2005, is one of 18 in phase 3, and was the 2nd registered.
8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →2 of the 41 studies testing Insulin, Regular, Human in Diabetes Mellitus are open now, in 1 country. Recruiting first, the newest first:
Mannkind Corporation · Sites in United States
Ages 6–17
Columbia University · Sites in United States
Ages 18–65
By country, each count listing its studies:
Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 4 · Phase 3 18 · Phase 4 9
First in 1989; this study’s year is marked. 3 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 299 is above the median of 80 across 6,026 interventional studies indexed under Diabetes Mellitus.
Median enrollment 60 across the 41 interventional studies. Of the 38 that completed or were terminated, 3 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 41 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
48 studies in Diabetes Mellitus by Eli Lilly and Company: none open now, 4 under way, 1 of them phase 3. Of 43 finished, 35 (81%) have results posted.
Among the 48 studies in Diabetes Mellitus by Eli Lilly and Company, this one is the 24th largest by enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2005, is one of 24 in phase 3, and was the 4th registered.
Eli Lilly and Company’s Diabetes Mellitus studies by the year they started, since 2001.
1 of the studies testing Insulin, Regular, Human in Diabetes Mellitus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07224321Mannkind CorporationINHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies testing Insulin, Regular, Human in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 48 in Diabetes Mellitus:
This tab as a report to print or save as PDF → With an account.
Phase 3 , open-label, randomized study to evaluate the safety and efficacy of the Lilly/Alkermes inhaled insulin system compared to injected insulin in type 1 and type 2 diabetes patients with asthma or COPD. Patients will be treated for 12 months with a 2 month follow up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Human Insulin Inhalation Powder
Drug: injected insulin
patient specific dose, inhaled, before meals, 12 months
Also known as: LY041001
patient specific dose, injected, before meals, 12 months.
To test the hypothesis that the glycemic control achieved with preprandial Human Insulin Inhalation Powder is noninferior to that achieved with injectable insulin, as measured by mean change from baseline to endpoint in HbA1c.
Time frame: 12 months
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on FEV1 and FVC before and after inhalation of bronchodilator.
Time frame: 12 months
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on the response to bronchodilator as measured by change between pre- and post- bronchodilator FEV1 and FVC
Time frame: 12 months
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on DLco.
Time frame: 12 months
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on total lung capacity
Time frame: 12 months
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on safety as assessed by insulin antibody levels, adverse events, and episodes of hypoglycemia
Time frame: 12 months
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on safety as assessed by chest x-rays.
Time frame: 12 months
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on safety as assessed by the St. George's Respiratory Questionnaire.
Time frame: 12 months
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on safety as assessed by the Six-Minute Walk Test with the Borg CR10 Scale.
Time frame: 12 months
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on proportion of patients who achieve or maintain HbA1c of less than or equal to 6.5% and who achieve or maintain HbA1c of < 7 %.
Time frame: 12 months
To compare the effects of preprandial Human Insulin Inhalation Powder and inj. insulin on proportion of pts with type 2 on oral agent(s) rand. to Human Insulin Inhalation Powder only or glargine only who do not reach an HbA1c <7.5 % after six months.
Time frame: 12 months
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on glycemic control as assessed by the 8-point-self monitored blood glucose profiles
Time frame: 12 months
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on insulin dose requirements ( including total, basal, and/or bolus insulin)
Time frame: 12 months
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on patient-reported outcomes questionnaires to assess general health status.
Time frame: 12 months
To compare the effects of preprandial Human Insulin Inhalation Powder and injectable insulin on resource utilization.
Time frame: 12 months
To assess insulin inhaler reliability in patients randomized to treatment with Human Insulin Inhalation Powder.
Time frame: throughout the study
To explore the impact of Human Insulin Inhalation Powder on peak flow and peak flow variability in the study with asthma patients.
Time frame: 12 months
Showing the first 100 of 101 sites across 16 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Aug 2005, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin, Regular, Human